Cargando…

Determination of Serum Progranulin in Patients with Untreated Familial Hypercholesterolemia

Background: Familial hypercholesterolemia (FH) is an autosomal dominant trait characterized by elevated LDL-C concentrations and is associated with an increased risk of premature atherosclerosis. Progranulin (PGRN) is a multifunctional protein that is known to have various anti-atherogenic effects....

Descripción completa

Detalles Bibliográficos
Autores principales: Nádró, Bíborka, Lőrincz, Hajnalka, Juhász, Lilla, Szentpéteri, Anita, Sztanek, Ferenc, Varga, Éva, Páll, Dénes, Paragh, György, Harangi, Mariann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032136/
https://www.ncbi.nlm.nih.gov/pubmed/35453521
http://dx.doi.org/10.3390/biomedicines10040771
_version_ 1784692566708453376
author Nádró, Bíborka
Lőrincz, Hajnalka
Juhász, Lilla
Szentpéteri, Anita
Sztanek, Ferenc
Varga, Éva
Páll, Dénes
Paragh, György
Harangi, Mariann
author_facet Nádró, Bíborka
Lőrincz, Hajnalka
Juhász, Lilla
Szentpéteri, Anita
Sztanek, Ferenc
Varga, Éva
Páll, Dénes
Paragh, György
Harangi, Mariann
author_sort Nádró, Bíborka
collection PubMed
description Background: Familial hypercholesterolemia (FH) is an autosomal dominant trait characterized by elevated LDL-C concentrations and is associated with an increased risk of premature atherosclerosis. Progranulin (PGRN) is a multifunctional protein that is known to have various anti-atherogenic effects. To date, the use of serum PGRN in patients with FH has not been studied. Methods: In total, 81 untreated patients with heterozygous FH (HeFH) and 32 healthy control subjects were included in this study. Serum PGRN, sICAM-1, sVCAM-1, oxLDL and TNFα concentrations were determined by ELISA. Lipoprotein subfractions were detected by Lipoprint. We diagnosed FH using the Dutch Lipid Clinic Network criteria. Results: We could not find a significant difference between the PGRN concentrations of the HeFH patients and controls (37.66 ± 9.75 vs. 38.43 ± 7.74 ng/mL, ns.). We found significant positive correlations between triglyceride, TNFα, sVCAM-1, the ratio of small HDL subfraction and PGRN, while significant negative correlations were found between the ratio of large HDL subfraction and PGRN both in the whole study population and in FH patients. PGRN was predicted by sVCAM-1, logTNFα and the ratio of small HDL subfraction. Conclusions: The strong correlations between HDL subfractions, inflammatory markers and PGRN suggest that PGRN may exert its anti-atherogenic effect in HeFH through the alteration of HDL composition and the amelioration of inflammation rather than through decreasing oxidative stress.
format Online
Article
Text
id pubmed-9032136
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90321362022-04-23 Determination of Serum Progranulin in Patients with Untreated Familial Hypercholesterolemia Nádró, Bíborka Lőrincz, Hajnalka Juhász, Lilla Szentpéteri, Anita Sztanek, Ferenc Varga, Éva Páll, Dénes Paragh, György Harangi, Mariann Biomedicines Article Background: Familial hypercholesterolemia (FH) is an autosomal dominant trait characterized by elevated LDL-C concentrations and is associated with an increased risk of premature atherosclerosis. Progranulin (PGRN) is a multifunctional protein that is known to have various anti-atherogenic effects. To date, the use of serum PGRN in patients with FH has not been studied. Methods: In total, 81 untreated patients with heterozygous FH (HeFH) and 32 healthy control subjects were included in this study. Serum PGRN, sICAM-1, sVCAM-1, oxLDL and TNFα concentrations were determined by ELISA. Lipoprotein subfractions were detected by Lipoprint. We diagnosed FH using the Dutch Lipid Clinic Network criteria. Results: We could not find a significant difference between the PGRN concentrations of the HeFH patients and controls (37.66 ± 9.75 vs. 38.43 ± 7.74 ng/mL, ns.). We found significant positive correlations between triglyceride, TNFα, sVCAM-1, the ratio of small HDL subfraction and PGRN, while significant negative correlations were found between the ratio of large HDL subfraction and PGRN both in the whole study population and in FH patients. PGRN was predicted by sVCAM-1, logTNFα and the ratio of small HDL subfraction. Conclusions: The strong correlations between HDL subfractions, inflammatory markers and PGRN suggest that PGRN may exert its anti-atherogenic effect in HeFH through the alteration of HDL composition and the amelioration of inflammation rather than through decreasing oxidative stress. MDPI 2022-03-25 /pmc/articles/PMC9032136/ /pubmed/35453521 http://dx.doi.org/10.3390/biomedicines10040771 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nádró, Bíborka
Lőrincz, Hajnalka
Juhász, Lilla
Szentpéteri, Anita
Sztanek, Ferenc
Varga, Éva
Páll, Dénes
Paragh, György
Harangi, Mariann
Determination of Serum Progranulin in Patients with Untreated Familial Hypercholesterolemia
title Determination of Serum Progranulin in Patients with Untreated Familial Hypercholesterolemia
title_full Determination of Serum Progranulin in Patients with Untreated Familial Hypercholesterolemia
title_fullStr Determination of Serum Progranulin in Patients with Untreated Familial Hypercholesterolemia
title_full_unstemmed Determination of Serum Progranulin in Patients with Untreated Familial Hypercholesterolemia
title_short Determination of Serum Progranulin in Patients with Untreated Familial Hypercholesterolemia
title_sort determination of serum progranulin in patients with untreated familial hypercholesterolemia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032136/
https://www.ncbi.nlm.nih.gov/pubmed/35453521
http://dx.doi.org/10.3390/biomedicines10040771
work_keys_str_mv AT nadrobiborka determinationofserumprogranulininpatientswithuntreatedfamilialhypercholesterolemia
AT lorinczhajnalka determinationofserumprogranulininpatientswithuntreatedfamilialhypercholesterolemia
AT juhaszlilla determinationofserumprogranulininpatientswithuntreatedfamilialhypercholesterolemia
AT szentpeterianita determinationofserumprogranulininpatientswithuntreatedfamilialhypercholesterolemia
AT sztanekferenc determinationofserumprogranulininpatientswithuntreatedfamilialhypercholesterolemia
AT vargaeva determinationofserumprogranulininpatientswithuntreatedfamilialhypercholesterolemia
AT palldenes determinationofserumprogranulininpatientswithuntreatedfamilialhypercholesterolemia
AT paraghgyorgy determinationofserumprogranulininpatientswithuntreatedfamilialhypercholesterolemia
AT harangimariann determinationofserumprogranulininpatientswithuntreatedfamilialhypercholesterolemia